Resilience at InterMune: A Journey Through the Valley of the Shadow of Death Harvard Case Solution & Analysis

Despite many setbacks, it ultimately succeeded in developing and getting approval for an orphan drug used to treat a deadly lung disease, IPF.

The protagonist, InterMune's CEO, Dan Welch, joined the company in 2003 and has directed InterMune through multiple divestitures, leadership changes, clinical trial disappointments, numerous tactical pivots, and ultimately the sale of the company. The capacity as well as resilience is at the center of this case study.

The story concentrates on leadership changes, and strategic, cultural and choices made by Welch, the Board and also the leadership team throughout the tenure of Welch. Especially, InterMune's tactical focus sharpened on a few indications, evolved the Board and the leadership team, and orchestrated a grassroots initiative to re-invent InterMune's core values and ethnic pillars.

This is just an excerpt. This case is about INNOVATION & ENTREPRENEURSHIP

PUBLICATION DATE: June 10, 2015 PRODUCT #: B5838-PDF-ENG

 

Resilience at InterMune: A Journey Through the Valley of the Shadow of Death Case Solution Other Similar Case Solutions like

Resilience at InterMune: A Journey Through the Valley of the Shadow of Death

Share This